MNKD vs NBIX: fair value comparison
MannKind Corporation and Neurocrine Biosciences, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, MNKD currently sits closer to the top of our discount ranking. MNKD carries the stronger quality grade.
| MNKD | NBIX | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $3.80 | $166.23 |
| 12-month range | $2.54–$6.01 | $131.78–$167.77 |
| Sector rank | #17 of 113 Healthcare | #18 of 113 Healthcare |
| Quality grade | A | C+ |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | High | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: MNKD fair value analysis · NBIX fair value analysis